Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy ... : vimarsana.com

NOVATO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases,

Related Keywords

United States , Oregon , Joshua Higa , Jeff Blake , Cary Harding , Erin Frey , Jan Panteli , Eric Himelman , Emily Belcher , Emild Kakkis , Rebecca Riba Wolman , Sam Wadsworth , June Kang , Maggie Wright , Laurie Tran , Heather Lau , Global Clinical Development , Linkedin , Ultragenyx Pharmaceutical Inc , Contacts Ultragenyx Pharmaceutical Inc , American Society Of Gene Cell Therapy , Oregon Health Science University Oral , Nasdaq , Exchange Commission , Government Affairs , Development Of High Density Purity , University Of Connecticut Poster , American Society , Cell Therapy , Annual Meeting , Accelerated Approval , Late Onset Ornithine Transcarbamylase , Oregon Health , Science University Oral , Sustained Efficacy , Three Years , Liver Directed Gene Therapy , Connecticut Poster , Improving Neuronal Gene Transfer , Brain After , Juvenile Non Human Primates , Ultragenyx Poster , Educational Needs , United States Physicians Related , Gene Therapy , Producer Cell Line , Highly Optimized Monoclonal Producer Cell Lines , High Density , High Purity , Vitro Model , Hwan June Kang , Chief Executive Officer , Gene Therapies , System That Keeps Pace , Gene Therapy Advances Time , State Government Affairs , Integration Time , Chief Scientific Officer , Ultragenyx Gene Therapywhat , Gene Therapy Clinical Trial Time , Executive Director , Ultragenyx Pharmaceutical , Looking Statements Except , Private Securities Litigation Reform Act , Quarterly Report , Money , Ational ,